ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA associated vasculitis"

  • Abstract Number: 1357 • ACR Convergence 2022

    The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage

    Annika Maunz1, Joerg Henes2, Joanna Robson3, Johann Jacoby4, Bernhard Hellmich5 and Christian Löffler6, 1Medius Kliniken - Teaching Hospital University of Tübingen, Kirchheim-Teck, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3UWE Bristol, Bristol, United Kingdom, 4University Hospital Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany, 5Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 6Medius Kliniken - Teaching Hospital University of Tübingen,, Kirchheim Teck, Germany

    Background/Purpose: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) is a new disease-specific PRO developed to capture the impact of having AAV and dealing with its treatment…
  • Abstract Number: 0442 • ACR Convergence 2022

    Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey

    Lilian Xu1, Faten Aqeel1, Ojaswi Tomar2, Tingting Li2 and Duvuru Geetha1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Washington University in St. Louis School of Medicine, St. Louis, MO

    Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…
  • Abstract Number: 0491 • ACR Convergence 2022

    Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis

    Despina Michailidou1, Bhargavi Duvvuri1, Runa Kuley1, David Cuthbertson2, Peter Grayson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Larry Moreland8, Christian Pagnoux9, Philip Seo10, Ulrich Specks11, Antoine Sreih7, Kenneth J. Warrington11, Tomas Mustelin1, Paul Monach12, Peter Merkel13 and Christian Lood1, 1Division of Rheumatology, University of Washington, Seattle, WA, 2University of South Florida, Tampa, FL, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Division of Rheumatology, Mc Master University, Ontario, Canada, Ontario, Canada, 5Division of Rheumatology, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, 6Cleveland Clinic, Cleveland, OH, 7Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 8University of Colorado, Denver, CO, 9Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 10Johns Hopkins University, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12VA Boston Healthcare System, Boston, MA, 13University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…
  • Abstract Number: 1079 • ACR Convergence 2022

    Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital

    Fabricio Benavides Villanueva1, Cristina Corrales1, Vanesa Calvo Río2, Javier Loricera3, Nuria Aviles4, Juan M Blanco Madrigal5, Santos Castañeda6, Miguel Angel Gonzalez Gay7 and Ricardo Blanco3, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Valdecilla Hospital, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Perpetuo Socorro, Albacete, Spain, 5Basurto University Hospital, Bilbao, Spain, 6Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 7Hospital Universitario Marques de Valdecilla, Lugo, Spain

    Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
  • Abstract Number: 1574 • ACR Convergence 2022

    Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System

    Alicia Rodriguez-Pla, Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…
  • Abstract Number: 0443 • ACR Convergence 2022

    Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis

    Aurélien Chepy1, Hélène Béhal2, Alexandre Karras3, Xavier Puéchal4, Benjamin Terrier4, David Jayne5, Thomas Quéméneur6 and Mary-Jane Guerry7, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 2University of Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France, 3HEGP, Paris, France, 4National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 5University of Cambridge, Cambridge, United Kingdom, 6Valenciennes Hospital, Valenciennes, France, 7Department of Nephrology, Centre Hospitalier de Valenciennes, Valenciennes., Valenciennes, France

    Background/Purpose: Immunosuppressive treatments have improved the prognosis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), transforming these formerly fatal diseases into chronic conditions, with periods of…
  • Abstract Number: 0513 • ACR Convergence 2022

    The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Jessica Bloom1, Kaci Pickett2, Lori Silveira2, David Cuthbertson3, Nader Khalidi4, Curry Koening5, Carol Langford6, Carol McAlear7, Paul Monach8, Larry Moreland1, Christian Pagnoux9, Rennie Rhee10, Philip Seo11, Ulrich Specks12, Kenneth J. Warrington12, Robert Fuhlbrigge1 and Peter Merkel10, 1University of Colorado, Denver, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of South Florida, Tampa, FL, 4McMaster University, Hamilton, ON, Canada, 5University of Texas Dell Medical School, Austin, TX, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania, Philadelphia, 8VA Boston Healthcare System, Boston, MA, 9Mount Sinai Hospital, Toronto, ON, Canada, 10University of Pennsylvania, Philadelphia, PA, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN

    Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…
  • Abstract Number: 1080 • ACR Convergence 2022

    Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
  • Abstract Number: 1615 • ACR Convergence 2022

    Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality

    Pavlos Stamatis1, Moman Mohammad2, David Erlinge2, Carl Turesson3, David Jayne4 and Aladdin Mohammad5, 1Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, 2Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4University of Cambridge, Cambridge, United Kingdom, 5Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden

    Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…
  • Abstract Number: 0444 • ACR Convergence 2022

    Prevalence of Frailty and Associated Factors in Patients with Vasculitis

    Sebastian Sattui1, John Stadler2, Cristina Burroughs3, Kalen Larson2, Christine Yeung4, Peter Merkel5 and Robert Spiera6, 1University of Pittsburgh, Pittsburgh, PA, 2Vasculitis Foundation, Kansas City, MO, 3University of South Florida, Tampa, FL, 4University of Pennsylvania, Philadelphia, 5University of Pennsylvania, Philadelphia, PA, 6Hospital for Special Surgery, New York, NY

    Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in…
  • Abstract Number: 0525 • ACR Convergence 2022

    Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial

    David Jayne1, Peter Merkel2, Frank Cortazar3, John Niles4 and Pirow Bekker5, 1University of Cambridge, Cambridge, United Kingdom, 2U of Pennsylvania, Philadelphia, PA, 3St. Peter's Hospital, Albany, NY, 4Harvard, Boston, MA, 5ChemoCentryx, San Juan Capistrano, CA

    Background/Purpose: In the 330-patient ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis, in which 81% of patients with ANCA-associated vasculitis had renal involvement,…
  • Abstract Number: 1081 • ACR Convergence 2022

    Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide

    Elizabeth Nettleton1, Sebastian Sattui2, Zachary Wallace3 and Mike Putman1, 1The Medical College of Wisconsin, Milwaukee, WI, 2University of Pittsburgh, Pittsburgh, PA, 3Massachusetts General Hospital, Boston, MA

    Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…
  • Abstract Number: 1688 • ACR Convergence 2022

    Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis

    Noelle Pisacano1, Stephen P. McAdoo1, Jochen Guck2, Charles D. Pusey1, Edwin R. Chilvers1, Andrew S. Cowburn1, Katharine M. Lodge1 and Maria F. Prendecki1, 1Imperial College London, London, United Kingdom, 2Max Planck Institute, Erlangen, Germany

    Background/Purpose: Real Time-Deformability Cytometry (RT-DC) is a novel technique able to identify morpho-rheological characteristics of individual cells such as size, deformability, and elasticity using only…
  • Abstract Number: 0445 • ACR Convergence 2022

    Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis

    Ana Arevalo1, Palak Shah2, Harshvardhan Zala3, Faris Haddadin4, Monil Majmundar5 and Andrea Ramirez Gomez1, 1University of Chicago, Chicago, IL, 2Metropolitan Hospital Center, New York Medical College, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Baylor College of Medicine, Houston, TX, 5University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Several studies have reported that patients with ANCA-associated vasculitis (AAV) are at increased risk of cardiovascular complications from accelerated atherosclerosis with an excess cardiovascular…
  • Abstract Number: 0526 • ACR Convergence 2022

    Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial

    Lynn Fussner1, Luis Felipe Flores-Suarez2, Rodrigo Cartin-Ceba3, Ulrich Specks3, P. Gerard Cox4, David Jayne5, Peter Merkel6 and Michael Walsh4, 1The Ohio State University, Columbus, OH, 2Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, 3Mayo Clinic, Rochester, MN, 4McMaster University, Hamilton, ON, Canada, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology